FDA Rejects Summit's Ivonescimab Lung Cancer Application

The FDA has rejected Summit Therapeutics' application for ivonescimab combined with platinum-containing chemotherapy for locally advanced or metastatic non-small cell lung cancer following prior EGFR tyrosine kinase inhibitor therapy. In a Complete Response Letter, the agency said substantial evidence of effectiveness had not been established without a statistically significant overall survival improvement.

The application was supported by HARMONi, a global, randomized, double-blind Phase 3 trial comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in patients with EGFR-mutated, non-squamous NSCLC previously treated with a third-generation EGFR inhibitor. The study had two primary endpoints: progression-free survival and overall survival.

HARMONi met its progression-free survival endpoint, but the primary overall survival analysis showed a positive trend that did not reach statistical significance. The FDA determined that the progression-free survival benefit, without statistically significant overall survival improvement, did not support a positive benefit-risk profile for approval.

Summit reported no new safety signals, with treatment-related adverse events prompting discontinuation of ivonescimab in 16 patients, or 7.3%, compared with placebo discontinuation in 11 patients, or 5.0%. Treatment-related deaths occurred in four patients, or 1.8%, receiving ivonescimab plus chemotherapy and five patients, or 2.3%, in the comparator arm.

Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, invented by Akeso and initially approved in China in May 2024. It remains investigational in Summit's licensed territories, including the United States and Europe, while the company continues Phase 2 and Phase 3 development across lung, colorectal, urothelial and renal cell cancers.

 

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion